CA3254998A1 - MCI-1 ANTAGONIST SALT AND SOLVATES FORMS - Google Patents

MCI-1 ANTAGONIST SALT AND SOLVATES FORMS

Info

Publication number
CA3254998A1
CA3254998A1 CA3254998A CA3254998A CA3254998A1 CA 3254998 A1 CA3254998 A1 CA 3254998A1 CA 3254998 A CA3254998 A CA 3254998A CA 3254998 A CA3254998 A CA 3254998A CA 3254998 A1 CA3254998 A1 CA 3254998A1
Authority
CA
Canada
Prior art keywords
crystalline form
amg
xrpd pattern
radiation
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3254998A
Other languages
English (en)
French (fr)
Inventor
Henry Morrison
Jason S. Tedrow
Stephan D. PARENT
Courtney JOHNSON
Travis HOUSTON
Melanie BEVILL
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CA3254998A1 publication Critical patent/CA3254998A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3254998A 2022-04-05 2023-04-05 MCI-1 ANTAGONIST SALT AND SOLVATES FORMS Pending CA3254998A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263327659P 2022-04-05 2022-04-05
US63/327,659 2022-04-05
PCT/US2023/017504 WO2023196360A1 (en) 2022-04-05 2023-04-05 Salt forms and solvates of mci-1 antagonists

Publications (1)

Publication Number Publication Date
CA3254998A1 true CA3254998A1 (en) 2023-10-12

Family

ID=86386785

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3254998A Pending CA3254998A1 (en) 2022-04-05 2023-04-05 MCI-1 ANTAGONIST SALT AND SOLVATES FORMS

Country Status (9)

Country Link
US (1) US12351588B2 (enExample)
EP (1) EP4504737A1 (enExample)
JP (1) JP2025513774A (enExample)
AU (1) AU2023249146A1 (enExample)
CA (1) CA3254998A1 (enExample)
MX (1) MX2024012192A (enExample)
TW (1) TW202404983A (enExample)
UY (1) UY40217A (enExample)
WO (1) WO2023196360A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4519271A1 (en) 2022-05-04 2025-03-12 Gilead Sciences, Inc. Salts and polymorphs of certain mcl-1 inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3474B1 (ar) 2014-08-29 2020-07-05 Amgen Inc مشتقات تيتراهيدرونافثالين التي تثبط بروتين mcl-1

Also Published As

Publication number Publication date
MX2024012192A (es) 2024-11-08
US20230312602A1 (en) 2023-10-05
TW202404983A (zh) 2024-02-01
JP2025513774A (ja) 2025-04-30
US12351588B2 (en) 2025-07-08
AU2023249146A1 (en) 2024-10-10
WO2023196360A1 (en) 2023-10-12
EP4504737A1 (en) 2025-02-12
UY40217A (es) 2023-10-31

Similar Documents

Publication Publication Date Title
CA3047776C (en) Preparation, uses and solid forms of obeticholic acid
US11230533B2 (en) Crystalline salts and polymorphs of a P2X3 antagonist
AU2014286047A1 (en) Crystalline forms of ponatinib hydrochloride
US12351588B2 (en) Salt forms and solvates of Mcl-1 antagonists
KR20240000540A (ko) (s)-n-(3-(2-(((r)-1-하이드록시프로판-2-일)아미노)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-3-(2,2,2-트리플루오로에틸)피롤리딘-1-카르복스아미드 및 이의 염의 고체 상태 형태
US20240140966A1 (en) Amorphous and crystalline forms of mcl-1 antagonists
US20250115622A1 (en) Crystalline Forms Of An MCL-1 Inhibitor
US20250122224A1 (en) Crystalline Salt and Solvate Forms Of Murizatoclax (AMG 397)
EP3398946A1 (en) Salt of morpholine derivative and crystalline form thereof, as well as preparation method, pharmaceutical composition and use of the same
US20250002453A1 (en) Pharmaceutically acceptable salt of eliglustat and crystal form thereof
TW202216726A (zh) 八氫噻吩并喹啉化合物之琥珀酸鹽及其結晶
AU2023343417B2 (en) Psilocin crystalline forms
JP6907439B2 (ja) チエノピリミジン化合物の塩酸塩の結晶形
TW202413369A (zh) 呋喃嘧啶化合物酸加成鹽之晶形及藥物組成物
AU2022234309B2 (en) Crystalline salt of a multi-tyrosine kinase inhibitor, method of preparation, and use thereof
US20260085039A1 (en) Psilocin crystalline forms
WO2025228973A1 (en) Cocrystals of n-{cis-3-[methyl(7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino]cyclobutyl}propane-1-sulfonamide
KR20210017070A (ko) 신규한 티카그렐러의 결정형, 이의 제조방법 또는 용도

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240920

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250214

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250214

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250214

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250220

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250328

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250328

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260319

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260319